Tumor Ablator Trials Travel Drug Path, But Sponsor Seeks Device Regulation
This article was originally published in The Gray Sheet
Executive Summary
Genetronics Biomedical is in talks with FDA to pursue clinical development of the MedPulsor tumor ablation system through a device regulatory route